Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Published:2017-11-16 Issue:20 Volume:130 Page:2196-2203
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Moskowitz Alison J.¹^ORCID,Schöder Heiko²,Gavane Somali³,Thoren Katie L.⁴,Fleisher Martin⁴,Yahalom Joachim¹,McCall Susan J.¹,Cadzin Briana R.¹,Fox Stephanie Y.¹,Gerecitano John¹,Grewal Ravinder²,Hamlin Paul A.¹,Horwitz Steven M.¹,Kumar Anita¹,Matasar Matthew¹,Ni Andy⁵,Noy Ariela¹,Palomba M. Lia¹,Perales Miguel-Angel¹,Portlock Carol S.¹,Sauter Craig¹,Straus David¹,Younes Anas¹,Zelenetz Andrew D.¹,Moskowitz Craig H.¹

Affiliation:

1. Lymphoma Service and

2. Nuclear Medicine Department, Memorial Sloan Kettering Cancer Center, New York, NY;

3. Nuclear Medicine Department, Mt. Sinai Hospital, New York, NY; and

4. Clinical Chemistry Service and

5. Biostatistics Department, Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

Key PointsBaseline metabolic tumor volume and the presence of refractory disease predict outcome for patients with relapsed/refractory HL. Metabolic tumor volume improves the predictive power of pretransplantation PET in relapsed/refractory HL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/20/2196/1403286/blood788877.pdf

Reference33 articles.

1. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial;Schmitz;Lancet,2002

2. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial;Linch;Lancet,1993

3. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma;Moskowitz;Blood,2012

4. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease;Josting;Ann Oncol,2002

5. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804;Bartlett;Ann Oncol,2007

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Novel Quantitative Imaging Techniques in Hematological Malignancies;PET Clinics;2024-10

2. Hodgkin Lymphoma: Next Questions;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience;Clinical Genitourinary Cancer;2024-08

4. Hodgkin lymphoma and liquid biopsy: a story to be told;Journal of Experimental & Clinical Cancer Research;2024-07-02

5. Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges;Expert Review of Hematology;2024-06-27